LIVIVO - Search results -

Search results

Result 1 - 10 of total 115

Search options

Article ; Online: Biomedical applications of cerium vanadate nanoparticles: a review.

Farasati Far, Bahareh / Maleki-Baladi, Reza / Fathi-Karkan, Sonia / Babaei, Meisam / Sargazi, Saman

2024 Volume 12, Issue 3, Page(s) 609–636

Abstract: Cerium vanadate nanoparticles ( ... ...

Abstract	Cerium vanadate nanoparticles (CeVO
MeSH term(s)	Vanadates/pharmacology ; Vanadates/chemistry ; Cerium/pharmacology ; Cerium/chemistry ; Tissue Distribution ; Prospective Studies ; Nanoparticles/chemistry
Chemical Substances	Vanadates (3WHH0066W5) ; Cerium (30K4522N6T)
Language	English
Publishing date	2024-01-17
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2702241-9
ISSN	2050-7518 ; 2050-750X
ISSN (online)	2050-7518
ISSN	2050-750X
DOI	10.1039/d3tb01786a
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: New insights into targeted therapy of glioblastoma using smart nanoparticles.

Ghaznavi, Habib / Afzalipour, Reza / Khoei, Samideh / Sargazi, Saman / Shirvalilou, Sakine / Sheervalilou, Roghayeh

Cancer cell international

2024 Volume 24, Issue 1, Page(s) 160

Abstract: In recent times, the intersection of nanotechnology and biomedical research has given rise to nanobiomedicine, a captivating realm that holds immense promise for revolutionizing diagnostic and therapeutic approaches in the field of cancer. This ... ...

Abstract	In recent times, the intersection of nanotechnology and biomedical research has given rise to nanobiomedicine, a captivating realm that holds immense promise for revolutionizing diagnostic and therapeutic approaches in the field of cancer. This innovative fusion of biology, medicine, and nanotechnology aims to create diagnostic and therapeutic agents with enhanced safety and efficacy, particularly in the realm of theranostics for various malignancies. Diverse inorganic, organic, and hybrid organic-inorganic nanoparticles, each possessing unique properties, have been introduced into this domain. This review seeks to highlight the latest strides in targeted glioblastoma therapy by focusing on the application of inorganic smart nanoparticles. Beyond exploring the general role of nanotechnology in medical applications, this review delves into groundbreaking strategies for glioblastoma treatment, showcasing the potential of smart nanoparticles through in vitro studies, in vivo investigations, and ongoing clinical trials.
Language	English
Publishing date	2024-05-07
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2091573-1
ISSN	1475-2867
ISSN	1475-2867
DOI	10.1186/s12935-024-03331-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Composition, preparation methods, and applications of nanoniosomes as codelivery systems: a review of emerging therapies with emphasis on cancer.

Roostaee, Maryam / Derakhshani, Atefeh / Mirhosseini, Hadiseh / Banaee Mofakham, Elmira / Fathi-Karkan, Sonia / Mirinejad, Shekoufeh / Sargazi, Saman / Barani, Mahmood

Nanoscale

2024 Volume 16, Issue 6, Page(s) 2713–2746

Abstract: Nanoniosome-based drug codelivery systems have become popular therapeutic instruments, demonstrating tremendous promise in cancer therapy, infection treatment, and other therapeutic domains. An emerging form of vesicular nanocarriers, niosomes are self- ... ...

Abstract	Nanoniosome-based drug codelivery systems have become popular therapeutic instruments, demonstrating tremendous promise in cancer therapy, infection treatment, and other therapeutic domains. An emerging form of vesicular nanocarriers, niosomes are self-assembling vesicles composed of nonionic surfactants, along with cholesterol or other amphiphilic molecules. This comprehensive review focuses on how nanosystems may aid in making anticancer and antibacterial pharmaceuticals more stable and soluble. As malleable nanodelivery instruments, the composition, types, preparation procedures, and variables affecting the structure and stability of niosomes are extensively investigated. In addition, the advantages of dual niosomes for combination therapy and the administration of multiple medications simultaneously are highlighted. Along with categorizing niosomal drug delivery systems, a comprehensive analysis of various preparation techniques, including thin-layer injection, ether injection, and microfluidization, is provided. Dual niosomes for cancer treatment are discussed in detail regarding the codelivery of two medications and the codelivery of a drug with organic, plant-based bioactive compounds or gene agents. In addition, niogelosomes and metallic niosomal carriers for targeted distribution are discussed. The review also investigates the simultaneous delivery of bioactive substances and gene agents, including siRNA, microRNA, shRNA, lncRNA, and DNA. Additional sections discuss the use of dual niosomes for cutaneous drug delivery and treating leishmanial infections,
MeSH term(s)	Liposomes/chemistry ; Drug Delivery Systems/methods ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Administration, Cutaneous ; Combined Modality Therapy ; Neoplasms/drug therapy
Chemical Substances	Liposomes ; Antineoplastic Agents
Language	English
Publishing date	2024-02-08
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2515664-0
ISSN	2040-3372 ; 2040-3364
ISSN (online)	2040-3372
ISSN	2040-3364
DOI	10.1039/d3nr03495j
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Exploring the potential of silymarin-loaded nanovesicles as an effective drug delivery system for cancer therapy: in vivo, in vitro, and in silico experiments.

Hajinezhad, Mohammad Reza / Roostaee, Maryam / Nikfarjam, Zahra / Rastegar, Sanaz / Sargazi, Ghasem / Barani, Mahmood / Sargazi, Saman

Naunyn-Schmiedeberg's archives of pharmacology

2024

Abstract: We aimed to perform a comprehensive study on the development and characterization of silymarin (Syl)-loaded niosomes as potential drug delivery systems. The results demonstrate significant novelty and promising outcomes in terms of morphology, size ... ...

Abstract	We aimed to perform a comprehensive study on the development and characterization of silymarin (Syl)-loaded niosomes as potential drug delivery systems. The results demonstrate significant novelty and promising outcomes in terms of morphology, size distribution, encapsulation efficiency, in vitro release behavior, free energy profiles of Syl across the niosome bilayer, hydrogen bonding interactions, antimicrobial properties, cytotoxicity, and in vivo evaluations. The physical appearance, size, and morphology assessment of free niosomes and Syl-loaded niosomes indicated stable and well-formed vesicular structures suitable for drug delivery. Transmission electron microscopy (TEM) analysis revealed spherical shapes with distinct sizes for each formulation, confirming uniform distribution. Dynamic light scattering (DLS) analysis confirmed the size distribution results with higher polydispersity index for Syl-loaded niosomes. The encapsulation efficiency of Syl in the niosomes was remarkable at approximately 91%, ensuring protection and controlled release of the drug. In vitro release studies showed a sustained release profile for Syl-loaded niosomes, enhancing therapeutic efficacy over time. Free energy profiles analysis identified energy barriers hindering Syl permeation through the niosome bilayer, emphasizing challenges in drug delivery system design. Hydrogen bonding interactions between Syl and niosome components contributed to energy barriers, impacting drug permeability. Antimicrobial assessments revealed significant differences in inhibitory effects against S. aureus and E. coli. Cytotoxicity evaluations demonstrated the superior tumor-killing potential of Syl-loaded niosomes compared to free Syl. In vivo studies indicated niosome formulations' safety profiles in terms of liver and kidney parameters compared to bulk Syl, showcasing potential for clinical applications. Overall, this research highlights the promising potential of Syl-loaded niosomes as effective drug delivery systems with enhanced stability, controlled release, and improved therapeutic outcomes.
Language	English
Publishing date	2024-04-17
Publishing country	Germany
Document type	Journal Article
ZDB-ID	121471-8
ISSN	1432-1912 ; 0028-1298
ISSN (online)	1432-1912
ISSN	0028-1298
DOI	10.1007/s00210-024-03099-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.5: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Nanotherapeutic approaches for delivery of long non-coding RNAs: an updated review with emphasis on cancer.

Davodabadi, Fatemeh / Mirinejad, Shekoufeh / Malik, Sumira / Dhasmana, Archna / Ulucan-Karnak, Fulden / Sargazi, Sara / Sargazi, Saman / Fathi-Karkan, Sonia / Rahdar, Abbas

Nanoscale

2024 Volume 16, Issue 8, Page(s) 3881–3914

Abstract: The long noncoding RNAs (lncRNAs) comprise a wide range of RNA species whose length exceeds 200 nucleotides, which regulate the expression of genes and cellular functions in a wide range of organisms. Several diseases, including malignancy, have been ... ...

Abstract	The long noncoding RNAs (lncRNAs) comprise a wide range of RNA species whose length exceeds 200 nucleotides, which regulate the expression of genes and cellular functions in a wide range of organisms. Several diseases, including malignancy, have been associated with lncRNA dysregulation. Due to their functions in cancer development and progression, lncRNAs have emerged as promising biomarkers and therapeutic targets in cancer diagnosis and treatment. Several studies have investigated the anti-cancer properties of lncRNAs; however, only a few lncRNAs have been found to exhibit tumor suppressor properties. Furthermore, their length and poor stability make them difficult to synthesize. Thus, to overcome the instability of lncRNAs, poor specificity, and their off-target effects, researchers have constructed nanocarriers that encapsulate lncRNAs. Recently, translational medicine research has focused on delivering lncRNAs into tumor cells, including cancer cells, through nano-drug delivery systems
MeSH term(s)	Humans ; RNA, Long Noncoding/genetics ; RNA, Long Noncoding/metabolism ; Neoplasms/drug therapy ; Neoplasms/genetics ; Biomarkers, Tumor/metabolism ; Exosomes/metabolism ; Gene Expression Regulation, Neoplastic
Chemical Substances	RNA, Long Noncoding ; Biomarkers, Tumor
Language	English
Publishing date	2024-02-22
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2515664-0
ISSN	2040-3372 ; 2040-3364
ISSN (online)	2040-3372
ISSN	2040-3364
DOI	10.1039/d3nr05656b
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: IGF2BP2 and IGFBP3 Genotypes, Haplotypes, and Genetic Models Studies in Polycystic Ovary Syndrome.

Govahi Kakhki, Fatemeh / Sargazi, Saman / Montazerifar, Farzaneh / Majidpour, Mahdi / Karajibani, Atena / Karajibani, Mansour / Ghasemi, Marzieh

Journal of clinical laboratory analysis

2024 Volume 38, Issue 5, Page(s) e25021

Abstract: Background: Insulin resistance has been correlated with the genetic diversity within the insulin-like binding proteins genes. Moreover, insulin resistance is one of the key characteristics of the widespread reproductive endocrine condition known as ... ...

Abstract	Background: Insulin resistance has been correlated with the genetic diversity within the insulin-like binding proteins genes. Moreover, insulin resistance is one of the key characteristics of the widespread reproductive endocrine condition known as polycystic ovarian syndrome (PCOS). Hence, this study is aimed to determine the association between IGFBP3 and IGF2BP2 gene variants and PCOS risk. Methods: A total of 300 subjects (150 PCOS cases diagnosed based on Rotterdam ESHRE/ASRM consensus criteria and 150 healthy subjects) were recruited in this case-control cross-sectional study. Tetra-primer amplification refractory mutation system polymerase chain reaction (ARMS-PCR) was used for genotyping rs11705701, whereas genotyping of rs1470579 and rs2854744 was done employing PCR-restriction fragment length polymorphism (PCR-RFLP) technique. Results: The CC and AA+AC genotypes of rs1470579 conferred an increased risk of PCOS in our population. Regarding the rs2854744, an increased risk of PCOS was observed under the codominant homozygous (TT vs. GG) model by 2.54 fold. The C allele of rs1470579 and T allele of rs2854744 enhanced PCOS risk by 1.97 and 1.46 folds, respectively. Haplotype analysis showed that the A Conclusions: IGF2BP2 rs1470579 and IGFBP3 rs2854744 enhanced PCOS susceptibility in a Southeastern Iranian population. Further investigation involving larger cohorts representing diverse ethnic backgrounds is needed to confirm the current findings.
MeSH term(s)	Female ; Humans ; Polycystic Ovary Syndrome/epidemiology ; Polycystic Ovary Syndrome/genetics ; Polycystic Ovary Syndrome/metabolism ; Insulin Resistance/genetics ; Genetic Predisposition to Disease/genetics ; Haplotypes/genetics ; Polymorphism, Single Nucleotide/genetics ; Cross-Sectional Studies ; Iran/epidemiology ; Models, Genetic ; Case-Control Studies ; Genotype ; Gene Frequency/genetics ; RNA-Binding Proteins/genetics ; Insulin-Like Growth Factor Binding Protein 3/genetics
Chemical Substances	IGF2BP2 protein, human ; RNA-Binding Proteins ; IGFBP3 protein, human ; Insulin-Like Growth Factor Binding Protein 3
Language	English
Publishing date	2024-03-11
Publishing country	United States
Document type	Journal Article
ZDB-ID	645095-7
ISSN	1098-2825 ; 0887-8013
ISSN (online)	1098-2825
ISSN	0887-8013
DOI	10.1002/jcla.25021
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2471: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Recent advances in iron oxide nanoparticles for brain cancer theranostics: from

Sheervalilou, Roghayeh / Shirvaliloo, Milad / Sargazi, Saman / Ghaznavi, Habib

Expert opinion on drug delivery

2021 Volume 18, Issue 7, Page(s) 949–977

Abstract: ... ...

Abstract	Introduction
MeSH term(s)	Brain Neoplasms/diagnostic imaging ; Brain Neoplasms/drug therapy ; Ferric Compounds ; Humans ; Magnetic Iron Oxide Nanoparticles ; Magnetic Resonance Imaging ; Magnetite Nanoparticles ; Nanoparticles ; Precision Medicine
Chemical Substances	Ferric Compounds ; Magnetite Nanoparticles
Language	English
Publishing date	2021-04-01
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2167286-6
ISSN	1744-7593 ; 1742-5247
ISSN (online)	1744-7593
ISSN	1742-5247
DOI	10.1080/17425247.2021.1888926
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6012: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Association study to evaluate Foxo1 and Foxo3 gene polymorphisms in polycystic ovary syndrome: a preliminary case–control study and in silico analysis

Rakhshani Nejad, Arghavan / Sargazi, Saman / Ghasemi, Marzieh / Samareh Moosavi, Saeedeh / Heidari Nia, Milad / Saravani, Ramin

Mol Biol Rep. 2023 Apr., v. 50, no. 4 p.3569-3580

2023

Abstract: BACKGROUND: Polycystic ovary syndrome (PCOS) is known as a multifactorial and multi-gene-mediated endocrine disorder among women of reproductive age. FoxO1 and FoxO3 are members of the forkhead transcriptional factors family that play a pivotal role in ... ...

Abstract	BACKGROUND: Polycystic ovary syndrome (PCOS) is known as a multifactorial and multi-gene-mediated endocrine disorder among women of reproductive age. FoxO1 and FoxO3 are members of the forkhead transcriptional factors family that play a pivotal role in the function of ovaries. The current work is aimed at investigating the association between gene variants of FoxO1 and FoxO3 and the risk of PCOS in a sample of the Iranian population. METHODS AND RESULTS: We recruited 200 women diagnosed with PCOS and 200 healthy women. Both polymerase PCR–RFLP and ARMS-PCR methods were used for genotyping. Sanger sequencing was recruited to confirm the genotyping results. The T allele of rs17592236 and the C allele of rs12585277 decreased PCOS risk by 29 and 28%, respectively. In contrast, the C allele of rs2253310 and G allele of rs2802292 increased the risk of PCOS by 1.39 and 1.63 folds, correspondingly. Bioinformatics results showed that some genes, including matrix metallopeptidase 9 (MMP-9), phosphoinositide-3-Kinase Regulatory Subunit 224 1 (PIK3R1), peroxisome proliferator-activated receptor Gamma (PPARG), and glycogen synthase 225 kinase-3 beta (GSK-3 beta) have significant interactions with FoxO1, suggesting that FoxO1 might have crucial roles in regulating different signaling pathways in ovarian cells. CONCLUSION: We found that FoxO1 rs17592236C > T and rs12585277C > T had a protective role against PCOS, while FoxO3 rs2253310C > G and rs2802292G > T enhanced the risk of this metabolic disorder in our population. Additional studies on larger populations with varying races are needed to confirm these findings.
Keywords	alleles ; bioinformatics ; case-control studies ; computer simulation ; genotyping ; glycogen (starch) synthase ; metabolic diseases ; peroxisome proliferator-activated receptor gamma ; polycystic ovary syndrome ; protective effect ; risk ; tau-protein kinase ; transcription (genetics)
Language	English
Dates of publication	2023-04
Size	p. 3569-3580.
Publishing place	Springer Netherlands
Document type	Article ; Online
ZDB-ID	186544-4
ISSN	1573-4978 ; 0301-4851
ISSN (online)	1573-4978
ISSN	0301-4851
DOI	10.1007/s11033-023-08292-w
Database	NAL-Catalogue (AGRICOLA)

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Bonn / Germany

Z 78/728: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article: The effects of lycopene supplementation on insulin‐like growth factor‐1 and insulin‐like growth factor binding proteins: A systematic review of randomized controlled trials

Meshkini, Fatemeh / Ramezani‐Jolfaie, Nahid / Sargazi, Saman / Clark, Cain C.T. / Soltani, Sepideh

Phytotherapy research. 2022 Apr., v. 36, no. 4

2022

Abstract: Lycopene has been posited to regulate insulin‐like growth factor‐1 (IGF‐1). We aimed to conduct a systematic review of the effects of lycopene on circulating IGF‐1 and insulin‐like growth factor binding proteins (IGFBPs) in adults. A systematic search ... ...

Abstract	Lycopene has been posited to regulate insulin‐like growth factor‐1 (IGF‐1). We aimed to conduct a systematic review of the effects of lycopene on circulating IGF‐1 and insulin‐like growth factor binding proteins (IGFBPs) in adults. A systematic search was carried out in PubMed, Scopus, ISI Web of Science, and the Cochrane Library databases for randomized controlled trials (RCTs), published from inception until March 2020. A total of 11 studies fulfilled the selection criteria. Eleven studies examined the effect of lycopene supplementation on IGF‐1, one of which reported a significant reduction. Moreover, three, four, and ten studies were found for IGFBP‐1, IGFBP‐2, and IGFBP‐3, respectively; where one study found a significant increase in these proteins. In conclusion, no consistent modifying effect of lycopene supplementation on IGF‐1 and IGFBPs levels are evident in the literature. More research is needed to explore the effect of lycopene on IGF‐1 system.
Keywords	insulin-like growth factor I ; lycopene ; phytotherapy ; research ; systematic review
Language	English
Dates of publication	2022-04
Size	p. 1633-1643.
Publishing place	John Wiley & Sons, Ltd.
Document type	Article
Note	REVIEW
ZDB-ID	639136-9
ISSN	1099-1573 ; 0951-418X
ISSN (online)	1099-1573
ISSN	0951-418X
DOI	10.1002/ptr.7418
Database	NAL-Catalogue (AGRICOLA)

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 3092: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches

Davodabadi, Fatemeh / Sarhadi, Mohammad / Arabpour, Javad / Sargazi, Saman / Rahdar, Abbas / Díez-Pascual, Ana M.

Journal of controlled release. 2022 Sept., v. 349

2022

Abstract: Breast cancer (BC) is known to be a highly heterogeneous disease that is clinically subdivided into four primary molecular subtypes, each having distinct morphology and clinical implications. These subtypes are principally defined by hormone receptors ... ...

Abstract	Breast cancer (BC) is known to be a highly heterogeneous disease that is clinically subdivided into four primary molecular subtypes, each having distinct morphology and clinical implications. These subtypes are principally defined by hormone receptors and other proteins involved (or not involved) in BC development. BC therapeutic vaccines [including peptide-based vaccines, protein-based vaccines, nucleic acid-based vaccines (DNA/RNA vaccines), bacterial/viral-based vaccines, and different immune cell-based vaccines] have emerged as an appealing class of cancer immunotherapeutics when used alone or combined with other immunotherapies. Employing the immune system to eliminate BC cells is a novel therapeutic modality. The benefit of active immunotherapies is that they develop protection against neoplastic tissue and readjust the immune system to an anti-tumor monitoring state. Such immunovaccines have not yet shown effectiveness for BC treatment in clinical trials. In recent years, nanomedicines have opened new windows to increase the effectiveness of vaccinations to treat BC. In this context, some nanoplatforms have been designed to efficiently deliver molecular, cellular, or subcellular vaccines to BC cells, increasing the efficacy and persistence of anti-tumor immunity while minimizing undesirable side effects. Immunostimulatory nano-adjuvants, liposomal-based vaccines, polymeric vaccines, virus-like particles, lipid/calcium/phosphate nanoparticles, chitosan-derived nanostructures, porous silicon microparticles, and selenium nanoparticles are among the newly designed nanostructures that have been used to facilitate antigen internalization and presentation by antigen-presenting cells, increase antigen stability, enhance vaccine antigenicity and remedial effectivity, promote antigen escape from the endosome, improve cytotoxic T lymphocyte responses, and produce humoral immune responses in BC cells. Here, we summarized the existing subtypes of BC and shed light on immunomodulatory and nano-therapeutic strategies for BC vaccination. Finally, we reviewed ongoing clinical trials on BC vaccination and highlighted near-term opportunities for moving forward.
Keywords	DNA ; RNA ; T-lymphocytes ; antigens ; breast neoplasms ; calcium ; cytotoxicity ; immunostimulants ; lipids ; nanomedicine ; phosphates ; polymers ; selenium ; silicon ; vaccination
Language	English
Dates of publication	2022-09
Size	p. 844-875.
Publishing place	Elsevier B.V.
Document type	Article
ZDB-ID	632533-6
ISSN	1873-4995 ; 0168-3659
ISSN (online)	1873-4995
ISSN	0168-3659
DOI	10.1016/j.jconrel.2022.07.036
Database	NAL-Catalogue (AGRICOLA)

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2055: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito